Bonus Biogroup Stock Cash Flow From Operations
| BONS Stock | ILS 16.30 0.20 1.24% |
Bonus Biogroup fundamentals help investors to digest information that contributes to Bonus Biogroup's financial success or failures. It also enables traders to predict the movement of Bonus Stock. The fundamental analysis module provides a way to measure Bonus Biogroup's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bonus Biogroup stock.
Bonus |
Bonus Biogroup Company Cash Flow From Operations Analysis
Bonus Biogroup's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Bonus Biogroup Cash Flow From Operations | (39.84 M) |
Most of Bonus Biogroup's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bonus Biogroup is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Bonus Biogroup has (39.84 Million) in Cash Flow From Operations. This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The cash flow from operations for all Israel stocks is notably higher than that of the company.
Bonus Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bonus Biogroup's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bonus Biogroup could also be used in its relative valuation, which is a method of valuing Bonus Biogroup by comparing valuation metrics of similar companies.Bonus Biogroup is currently under evaluation in cash flow from operations category among its peers.
Bonus Fundamentals
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Current Valuation | 169.66 M | |||
| Shares Outstanding | 1.17 B | |||
| Shares Owned By Insiders | 49.72 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 3.39 X | |||
| EBITDA | (88.03 M) | |||
| Net Income | (90.08 M) | |||
| Cash And Equivalents | 3.6 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 6.28 M | |||
| Current Ratio | 0.35 X | |||
| Book Value Per Share | 0.12 X | |||
| Cash Flow From Operations | (39.84 M) | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 13 | |||
| Beta | 1.4 | |||
| Market Capitalization | 223.15 M | |||
| Total Asset | 104.32 M | |||
| Z Score | 21.0 | |||
| Net Asset | 104.32 M |
About Bonus Biogroup Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bonus Biogroup's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bonus Biogroup using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bonus Biogroup based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Bonus Stock
Bonus Biogroup financial ratios help investors to determine whether Bonus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bonus with respect to the benefits of owning Bonus Biogroup security.